2024 Adverse Reactions Pharmaceutical Companies 
European Pharmaceutical Review
NOVEMBER 13, 2023
The pharmaceutical company also highlighted that the decision was additionally supported by data from a subpopulation of adult patients with moderate to severe anaemia from the SIMPLIFY-1 Phase III trial. GSK shared that a decision on marketing authorisation for momelotinib in the EU is expected by early 2024.
Hospital Pharmacy Europe
NOVEMBER 9, 2023
It also allows pharmaceutical companies to monitor product information and keep it constantly updated, as well as offering healthcare professionals and patients greater accessibility. Pharmaceutical companies participating in the pilot create and submit the ePI via the PLM Portal as part of their regulatory application.
Expert insights. Personalized for you.
109 
Let's personalize your content